CNSX:AGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non–alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Algernon Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.3%

AGN

-6.2%

CA Pharmaceuticals

-4.5%

CA Market


1 Year Return

237.5%

AGN

-20.3%

CA Pharmaceuticals

-8.8%

CA Market

Return vs Industry: AGN exceeded the Canadian Pharmaceuticals industry which returned -20.3% over the past year.

Return vs Market: AGN exceeded the Canadian Market which returned -8.8% over the past year.


Shareholder returns

AGNIndustryMarket
7 Day-5.3%-6.2%-4.5%
30 Day-14.3%14.0%-3.8%
90 Day-21.7%-1.2%-3.3%
1 Year237.5%237.5%-20.3%-20.3%-5.5%-8.8%
3 Year92.9%92.9%-28.2%-28.9%0.5%-9.2%
5 Yearn/a154.2%152.2%28.7%8.9%

Price Volatility Vs. Market

How volatile is Algernon Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Algernon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGN is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: AGN is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGN is overvalued based on its PB Ratio (2.2x) compared to the CA Pharmaceuticals industry average (1.3x).


Next Steps

Future Growth

How is Algernon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

57.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Algernon Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Algernon Pharmaceuticals performed over the past 5 years?

11.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGN is currently unprofitable.

Growing Profit Margin: AGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGN is unprofitable, but has reduced losses over the past 5 years at a rate of 11.5% per year.

Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%).


Return on Equity

High ROE: AGN has a negative Return on Equity (-44.77%), as it is currently unprofitable.


Next Steps

Financial Health

How is Algernon Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AGN's short term assets (CA$9.4M) exceed its short term liabilities (CA$1.1M).

Long Term Liabilities: AGN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AGN is debt free.

Reducing Debt: AGN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AGN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 19.5% each year.


Next Steps

Dividend

What is Algernon Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Chris Moreau (54 yo)

2.58yrs

Tenure

CA$108,000

Compensation

Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer at Algernon Pharmaceuticals Inc. (f.k.a. Breathtec Biomedical Inc.) since March 1, 2018 and serves its Director since May 13 ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD81.13K) is below average for companies of similar size in the Canadian market ($USD171.75K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Moreau
CEO & Director2.58yrsCA$108.00k0.65%
CA$ 256.5k
Michael S. Sadhra
CFO & Director5yrsCA$48.00k0.19%
CA$ 75.2k
Mark Williams
Chief Science Officer2yrsCA$138.49kno data

2.6yrs

Average Tenure

Experienced Management: AGN's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Moreau
CEO & Director2.58yrsCA$108.00k0.65%
CA$ 256.5k
Michael S. Sadhra
CFO & Director5yrsCA$48.00k0.19%
CA$ 75.2k
Howard Gutman
Member of Business Advisory Board0.50yrno datano data
Arun Sanyal
Member of Medical & Scientific Advisory Board1.58yrsno datano data
Rajpaul Attariwala
Independent Director5yrsno data0.72%
CA$ 285.0k
David Levine
Independent Director5yrsno datano data
Walter Reinisch
Member of Medical & Scientific Advisory Board1.5yrsno datano data
Martin Kolb
Member of Medical & Scientific Advisory Board0.83yrno datano data
Jacky Smith
Member of Medical & Scientific Advisory Board0.67yrno datano data
Mark Swaim
Member of Medical and Scientific Advisory Boardno datano datano data

1.5yrs

Average Tenure

53yo

Average Age

Experienced Board: AGN's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 192.9%.


Top Shareholders

Company Information

Algernon Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Algernon Pharmaceuticals Inc.
  • Ticker: AGN
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$39.521m
  • Shares outstanding: 138.67m
  • Website: https://algernonpharmaceuticals.com

Location

  • Algernon Pharmaceuticals Inc.
  • 700 West Pender Street
  • Suite 915
  • Vancouver
  • British Columbia
  • V6C 1G8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGNCNSX (Canadian National Stock Exchange)YesCommon SharesCACADFeb 2016
AGWDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2016
AGNP.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 2016

Biography

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non–alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/29 00:46
End of Day Share Price2020/10/28 00:00
Earnings2020/05/31
Annual Earnings2019/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.